Literature DB >> 32441445

Frontline Science: CD40 signaling restricts RNA virus replication in Mϕs, leading to rapid innate immune control of acute virus infection.

Kai J Rogers1, Olena Shtanko2, Laura L Stunz1, Laura N Mallinger1, Tina Arkee3, Megan E Schmidt3, Dana Bohan3, Bethany Brunton1, Judith M White4, Steve M Varga1,3, Noah S Butler1,3, Gail A Bishop1,3,5,6, Wendy Maury1,3.   

Abstract

Many acute viral infections target tissue Mϕs, yet the mechanisms of Mϕ-mediated control of viruses are poorly understood. Here, we report that CD40 expressed by peritoneal Mϕs restricts early infection of a broad range of RNA viruses. Loss of CD40 expression enhanced virus replication as early as 12-24 h of infection and, conversely, stimulation of CD40 signaling with an agonistic Ab blocked infection. With peritoneal cell populations infected with the filovirus, wild-type (WT) Ebola virus (EBOV), or a BSL2 model virus, recombinant vesicular stomatitis virus encoding Ebola virus glycoprotein (rVSV/EBOV GP), we examined the mechanism conferring protection. Here, we demonstrate that restricted virus replication in Mϕs required CD154/CD40 interactions that stimulated IL-12 production through TRAF6-dependent signaling. In turn, IL-12 production resulted in IFN-γ production, which induced proinflammatory polarization of Mϕs, protecting the cells from infection. These CD40-dependent events protected mice against virus challenge. CD40-/- mice were exquisitely sensitive to intraperitoneal challenge with a dose of rVSV/EBOV GP that was sublethal to CD40+/+ mice, exhibiting viremia within 12 h of infection and rapidly succumbing to infection. This study identifies a previously unappreciated role for Mϕ-intrinsic CD40 signaling in controlling acute virus infection. ©2020 Society for Leukocyte Biology.

Entities:  

Keywords:  CD40; CD40 signaling; Ebola virus; IFN-γ; IL-12; Mϕ; RNA virus; TRAF6; filovirus; innate immunity; peritoneum; virus restriction

Mesh:

Substances:

Year:  2020        PMID: 32441445      PMCID: PMC7774454          DOI: 10.1002/JLB.4HI0420-285RR

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  80 in total

1.  Longitudinal peripheral blood transcriptional analysis of a patient with severe Ebola virus disease.

Authors:  John C Kash; Kathie-Anne Walters; Jason Kindrachuk; David Baxter; Kelsey Scherler; Krisztina B Janosko; Rick D Adams; Andrew S Herbert; Rebekah M James; Spencer W Stonier; Matthew J Memoli; John M Dye; Richard T Davey; Daniel S Chertow; Jeffery K Taubenberger
Journal:  Sci Transl Med       Date:  2017-04-12       Impact factor: 17.956

2.  Disruption of antigen-induced inflammatory responses in CD40 ligand knockout mice.

Authors:  X F Lei; Y Ohkawara; M R Stämpfli; C Mastruzzo; R A Marr; D Snider; Z Xing; M Jordana
Journal:  J Clin Invest       Date:  1998-03-15       Impact factor: 14.808

3.  Natural killer cell recognition of target cells expressing different antigens of vesicular stomatitis virus.

Authors:  J R Moller; B Rager-Zisman; P C Quan; A Schattner; D Panush; J K Rose; B R Bloom
Journal:  Proc Natl Acad Sci U S A       Date:  1985-04       Impact factor: 11.205

4.  Interleukin-12 production by dendritic cells. The role of CD40-CD40L interactions in Th1 T-cell responses.

Authors:  B L Kelsall; E Stüber; M Neurath; W Strober
Journal:  Ann N Y Acad Sci       Date:  1996-10-31       Impact factor: 5.691

5.  Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection.

Authors:  Thomas W Geisbert; Lisa E Hensley; Tom Larsen; Howard A Young; Douglas S Reed; Joan B Geisbert; Dana P Scott; Elliott Kagan; Peter B Jahrling; Kelly J Davis
Journal:  Am J Pathol       Date:  2003-12       Impact factor: 4.307

6.  In vitro and in vivo characterization of recombinant Ebola viruses expressing enhanced green fluorescent protein.

Authors:  Hideki Ebihara; Steven Theriault; Gabriele Neumann; Judie B Alimonti; Joan B Geisbert; Lisa E Hensley; Allison Groseth; Steven M Jones; Thomas W Geisbert; Yoshihiro Kawaoka; Heinz Feldmann
Journal:  J Infect Dis       Date:  2007-11-15       Impact factor: 5.226

7.  IL-12 stimulates an antiviral type 1 cytokine response but lacks adjuvant activity in IFN-gamma-receptor-deficient mice.

Authors:  V E Schijns; B L Haagmans; M C Horzinek
Journal:  J Immunol       Date:  1995-09-01       Impact factor: 5.422

8.  Autophagy-Associated Proteins Control Ebola Virus Internalization Into Host Cells.

Authors:  Olena Shtanko; Ann N Reyes; William T Jackson; Robert A Davey
Journal:  J Infect Dis       Date:  2018-11-22       Impact factor: 5.226

9.  ILC1 Confer Early Host Protection at Initial Sites of Viral Infection.

Authors:  Orr-El Weizman; Nicholas M Adams; Iona S Schuster; Chirag Krishna; Yuri Pritykin; Colleen Lau; Mariapia A Degli-Esposti; Christina S Leslie; Joseph C Sun; Timothy E O'Sullivan
Journal:  Cell       Date:  2017-10-19       Impact factor: 41.582

10.  Divergent Roles of Interferon-γ and Innate Lymphoid Cells in Innate and Adaptive Immune Cell-Mediated Intestinal Inflammation.

Authors:  Jennifer Brasseit; Cheong K C Kwong Chung; Mario Noti; Daniel Zysset; Nina Hoheisel-Dickgreber; Vera Genitsch; Nadia Corazza; Christoph Mueller
Journal:  Front Immunol       Date:  2018-01-24       Impact factor: 7.561

View more
  4 in total

1.  A Naturally Occurring Polymorphism in the Base of Sudan Virus Glycoprotein Decreases Glycoprotein Stability in a Species-Dependent Manner.

Authors:  Nicholas J Lennemann; Jacob Dillard; Natalie Ruggio; Ashley L Cooney; Grace A Schaack; Robert A Davey; Wendy Maury
Journal:  J Virol       Date:  2021-08-25       Impact factor: 5.103

2.  Compound FC-10696 Inhibits Egress of Marburg Virus.

Authors:  Ziying Han; Hong Ye; Jingjing Liang; Ariel Shepley-McTaggart; Jay E Wrobel; Allen B Reitz; Alison Whigham; Katrina N Kavelish; Michael S Saporito; Bruce D Freedman; Olena Shtanko; Ronald N Harty
Journal:  Antimicrob Agents Chemother       Date:  2021-06-17       Impact factor: 5.191

3.  Prognostic impacts of soluble immune checkpoint regulators and cytokines in patients with SARS-CoV-2 infection.

Authors:  Nuri Lee; Seri Jeong; Kibum Jeon; Min-Jeong Park; Wonkeun Song
Journal:  Front Immunol       Date:  2022-08-15       Impact factor: 8.786

4.  Formulation, Stability, Pharmacokinetic, and Modeling Studies for Tests of Synergistic Combinations of Orally Available Approved Drugs against Ebola Virus In Vivo.

Authors:  Courtney L Finch; Julie Dyall; Shuang Xu; Elizabeth A Nelson; Elena Postnikova; Janie Y Liang; Huanying Zhou; Lisa Evans DeWald; Craig J Thomas; Amy Wang; Xin Xu; Emma Hughes; Patrick J Morris; Jon C Mirsalis; Linh H Nguyen; Maria P Arolfo; Bryan Koci; Michael R Holbrook; Lisa E Hensley; Peter B Jahrling; Connie Schmaljohn; Lisa M Johansen; Gene G Olinger; Joshua T Schiffer; Judith M White
Journal:  Microorganisms       Date:  2021-03-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.